Trial Profile
A Study to Compare Long-Term Safety and Tolerability of Stavudine (d4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulations, Each In Combination With Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studies AI455-096 and AI455-099.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Apr 2011
Price :
$35
*
At a glance
- Drugs Stavudine (Primary) ; Efavirenz; Lamivudine
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Feb 2010 New trial record